Company Description: Aluda was founded to reexamine how fundamental cell processes are altered by disease, combining rational drug design with holistic objectives to make wider impact. We discovered that Vimentin, a filament protein with well-validated roles in disease, is druggable, creating a new kind of disease-modifying action that blocks how many cell processes that are normally protective and regenerative shift to over-stimulated and maladapted in disease. Lead small molecule ALD-R491 is ready for Phase I. Expert KOL and regulatory guidance outlines a viable plan to NDA filing in 36 months in sepsis, followed by expansion in Severe Crohn’s with fibrotic strictures.